Metabolomics reveal potential natural substrates of AcrB in Escherichia coli and Salmonella enterica serovar Typhimurium
In the fight against antibiotic resistance, drugs that target resistance mechanisms in bacteria can be used to restore the therapeutic effectiveness of antibiotics. The multidrug resistance efflux complex AcrAB-TolC is the most clinically relevant efflux pump in Enterobacterales and is a target for...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
American Society for Microbiology
2021
|
| _version_ | 1826269536973750272 |
|---|---|
| author | Wang-Kan, X Rodríguez-Blanco, G Southam, AD Winder, CL Dunn, WB Ivens, A Piddock, LJV |
| author_facet | Wang-Kan, X Rodríguez-Blanco, G Southam, AD Winder, CL Dunn, WB Ivens, A Piddock, LJV |
| author_sort | Wang-Kan, X |
| collection | OXFORD |
| description | In the fight against antibiotic resistance, drugs that target resistance mechanisms in bacteria can be used to restore the therapeutic effectiveness of antibiotics. The multidrug resistance efflux complex AcrAB-TolC is the most clinically relevant efflux pump in Enterobacterales and is a target for drug discovery. Inhibition of the pump protein AcrB allows the intracellular accumulation of a wide variety of antibiotics, effectively restoring their therapeutic potency. To facilitate the development of AcrB efflux inhibitors, it is desirable to discover the native substrates of the pump, as these could be chemically modified to become inhibitors. We analyzed the native substrate profile of AcrB in Escherichia coli MG1655 and Salmonella enterica serovar Typhimurium SL1344 using an untargeted metabolomics approach. We analyzed the endo- and exometabolome of the wild-type strain and their respective AcrB loss-of-function mutants (AcrB D408A) to determine the metabolites that are native substrates of AcrB. Although there is 95% homology between the AcrB proteins of S. Typhimurium and E. coli, we observed mostly different metabolic responses in the exometabolomes of the S. Typhimurium and E. coli AcrB D408A mutants relative to those in the wild type, potentially indicating a differential metabolic adaptation to the same mutation in these two species. Additionally, we uncovered metabolite classes that could be involved in virulence of S. Typhimurium and a potential natural substrate of AcrB common to both species. |
| first_indexed | 2024-03-06T21:26:36Z |
| format | Journal article |
| id | oxford-uuid:434bef96-b450-47fa-bfea-8a44799c5a6a |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T21:26:36Z |
| publishDate | 2021 |
| publisher | American Society for Microbiology |
| record_format | dspace |
| spelling | oxford-uuid:434bef96-b450-47fa-bfea-8a44799c5a6a2022-03-26T14:54:36ZMetabolomics reveal potential natural substrates of AcrB in Escherichia coli and Salmonella enterica serovar TyphimuriumJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:434bef96-b450-47fa-bfea-8a44799c5a6aEnglishSymplectic ElementsAmerican Society for Microbiology 2021Wang-Kan, XRodríguez-Blanco, GSoutham, ADWinder, CLDunn, WBIvens, APiddock, LJVIn the fight against antibiotic resistance, drugs that target resistance mechanisms in bacteria can be used to restore the therapeutic effectiveness of antibiotics. The multidrug resistance efflux complex AcrAB-TolC is the most clinically relevant efflux pump in Enterobacterales and is a target for drug discovery. Inhibition of the pump protein AcrB allows the intracellular accumulation of a wide variety of antibiotics, effectively restoring their therapeutic potency. To facilitate the development of AcrB efflux inhibitors, it is desirable to discover the native substrates of the pump, as these could be chemically modified to become inhibitors. We analyzed the native substrate profile of AcrB in Escherichia coli MG1655 and Salmonella enterica serovar Typhimurium SL1344 using an untargeted metabolomics approach. We analyzed the endo- and exometabolome of the wild-type strain and their respective AcrB loss-of-function mutants (AcrB D408A) to determine the metabolites that are native substrates of AcrB. Although there is 95% homology between the AcrB proteins of S. Typhimurium and E. coli, we observed mostly different metabolic responses in the exometabolomes of the S. Typhimurium and E. coli AcrB D408A mutants relative to those in the wild type, potentially indicating a differential metabolic adaptation to the same mutation in these two species. Additionally, we uncovered metabolite classes that could be involved in virulence of S. Typhimurium and a potential natural substrate of AcrB common to both species. |
| spellingShingle | Wang-Kan, X Rodríguez-Blanco, G Southam, AD Winder, CL Dunn, WB Ivens, A Piddock, LJV Metabolomics reveal potential natural substrates of AcrB in Escherichia coli and Salmonella enterica serovar Typhimurium |
| title | Metabolomics reveal potential natural substrates of AcrB in Escherichia coli and Salmonella enterica serovar Typhimurium |
| title_full | Metabolomics reveal potential natural substrates of AcrB in Escherichia coli and Salmonella enterica serovar Typhimurium |
| title_fullStr | Metabolomics reveal potential natural substrates of AcrB in Escherichia coli and Salmonella enterica serovar Typhimurium |
| title_full_unstemmed | Metabolomics reveal potential natural substrates of AcrB in Escherichia coli and Salmonella enterica serovar Typhimurium |
| title_short | Metabolomics reveal potential natural substrates of AcrB in Escherichia coli and Salmonella enterica serovar Typhimurium |
| title_sort | metabolomics reveal potential natural substrates of acrb in escherichia coli and salmonella enterica serovar typhimurium |
| work_keys_str_mv | AT wangkanx metabolomicsrevealpotentialnaturalsubstratesofacrbinescherichiacoliandsalmonellaentericaserovartyphimurium AT rodriguezblancog metabolomicsrevealpotentialnaturalsubstratesofacrbinescherichiacoliandsalmonellaentericaserovartyphimurium AT southamad metabolomicsrevealpotentialnaturalsubstratesofacrbinescherichiacoliandsalmonellaentericaserovartyphimurium AT windercl metabolomicsrevealpotentialnaturalsubstratesofacrbinescherichiacoliandsalmonellaentericaserovartyphimurium AT dunnwb metabolomicsrevealpotentialnaturalsubstratesofacrbinescherichiacoliandsalmonellaentericaserovartyphimurium AT ivensa metabolomicsrevealpotentialnaturalsubstratesofacrbinescherichiacoliandsalmonellaentericaserovartyphimurium AT piddockljv metabolomicsrevealpotentialnaturalsubstratesofacrbinescherichiacoliandsalmonellaentericaserovartyphimurium |